Minerva Rockets On Positive PhIIb Data – Is A Big Pharma Partnership On The Horizon?
Minerva Neurosciences Inc.'s schizophrenia drug that targets patients with negative symptoms, an indication with high unmet need and no approved treatments, has met primary and secondary endpoints in a Phase IIb trial – positioning the company well for access to an open market and marking it as an attractive M&A target.
You may also be interested in...
Forum Pharmaceuticals' lead compound encenicline has failed to meet the endpoints in two Phase III trials for the treatment of cognitive impairment in schizophrenia patients. .
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.